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Abstract
Background and objective: Postoperative nausea and vomiting (PONV) occur frequently after 
laparoscopic bariatric surgery. The combination of haloperidol, dexamethasone, and ondansetron 
may reduce these undesirable events. The aim of this study was to evaluate the intensity of 
nausea and pain, the number of vomiting episodes, and morphine consumption in postoperative 
(PO) obese patients undergoing laparoscopic sleeve gastrectomy (LSG).
Method: A clinical, randomized, controlled, double-blind study conducted with 90 patients 
with body mass index ≥ 35 kg.cm-2. Patients were divided into three groups of 30 individuals 
to receive ondansetron 8 mg (Group O); ondansetron 8 mg and dexamethasone 8 mg (Group 
OD); and ondansetron 8 mg, dexamethasone 8 mg, and haloperidol 2 mg (Group HDO). We 
evaluated the intensity of nausea and pain using the verbal numeric scale, cumulative number 
of vomiting episodes, and morphine consumption in the period of 0-2, 2-12, 12-24, and 24-36 
hours postoperatively.
Results: Nausea intensity was lower in Group HDO compared to Group O (p = 0.001), pain intensity 
was lower in Group HDO compared to Group O (p = 0.046), and morphine consumption was lower 
in Group HDO compared to Group O (p = 0.037). There was no difference between groups regarding 
the number of vomiting episodes (p = 0.052).
Conclusion: The combination of haloperidol, ondansetron, and dexamethasone reduced nausea 
and pain intensity and morphine consumption in postoperative obese patients undergoing LSG.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Postoperative nausea and vomiting (PONV) usually occur 
after laparoscopic bariatric surgery. In previous studies, the 
incidence of PONV in patients who did not receive antieme-
tic prophylaxis was as high as 70-80%.1,2 The combination of 
antiemetic drugs has been used as a strategy for reducing 
PONV. Thus, the combination of three antiemetic drugs with 
different mechanisms of action may be an option to prevent 
these undesirable events.
Haloperidol, a prolonged action butyrophenone (18 hours) 
with high afﬁ nity for dopamine D2-receptors, has been used 
to control agitation and delirium in medical and surgical 
patients and in palliative care of cancer patients for nausea 
and vomiting management.3 It is used in much lower doses 
(1.2 mg) than drugs used for treating psychiatric disorders, 
administered by intravenous (IV) route for prevention and 
treatment of PONV with minimal toxicity. Extrapyramidal 
symptoms are rare and cardiac arrhythmias have not been 
reported.4,5
Intravenous dexamethasone (8-10 mg) reduces the 
incidence of PONV by a central mechanism that reduces 
the production of prostaglandin and controls the release 
of endorphins.6,7 Moreover, it may decrease postoperative 
pain by modulating the systemic physiological response of 
anti-inﬂ ammatory mediators.6 Despite the various potential 
side effects, such as infection and delayed wound healing 
or adrenal gland suppression, Henzi and colleagues did not 
observe these effects after a single bolus injection of dexa-
methasone in their systematic review.7
Ondansetron, one of the 5-HT3 receptor antagonists, is 
the most studied drug. Used intravenously at doses of 4-8 mg, 
it has few side effects and appears to be particularly useful 
for PONV in patients undergoing gastrointestinal surgery with 
stimulation of enterochromafﬁ n cells.8
Headaches may occur after its IV administration, and 
transient elevation of liver enzymes occurred in a small 
numbers of patients.9
Among the various types of surgical approaches to obesity, 
laparoscopic sleeve gastrectomy (LSG) is emerging.10
The aim of this study was to evaluate the intensity of nau-
sea, cumulative number of vomiting episodes, pain severity, 
and morphine consumption in postoperative obese patients 
undergoing LSG who received one of the three antiemetic 
prophylactic regimens.
Method
We conducted this study according to the Declaration of 
Helsinki Ethical principles and had it approved by the Medical 
Ethics Committee of the Universidade Federal de Mato Grosso 
(Protocol 932/CEP-HUJM/2010). We obtained written infor-
med consent from all patients. Between January and October 
2011, patients with age ≥ 18 years, physical status ASA I-III, 
body mass index (BMI) ≥ 35 kg.cm-2, and candidates for LSG 
were invited to participate in this randomized, controlled, 
double-blind, clinical trial. Exclusion criteria were patients 
with known hypersensitivity or contraindication to the study 
drugs; who had experienced serious complications during pe-
rioperative period; who have psychiatric disorder; history of 
migraine; and those who had used opioids, anti-inﬂ ammatory 
hormone, and antiemetic drugs 24 hours before surgery.
Patients, anesthesiologists, and investigators who collec-
ted the postoperative data were blinded to the randomization 
process and types of drugs used.
We used a list of random numbers generated by computer 
(www.graphpad.com) and the sealed envelope technique. 
Independent personnel not associated with the study prepa-
red the randomization. Thus, patients were assigned to recei-
ve one of three IV treatments. Group O (control): ondansetron 
(8 mg); Group DO: dexamethasone (8 mg) and ondansetron 
(8 mg); Group HDO: haloperidol (2 mg), dexamethasone (8 
mg) and ondansetron (8 mg). The nurse unit prepared the 
drugs in volumes of 10 mL with the same color (colorless) 
and delivered them to the assistant anesthesiologist who 
administered the volumes. Therefore, two syringes contai-
ning 0.9% saline solution (SS) or one containing SS and the 
other dexamethasone or one containing dexamethasone and 
the other haloperidol were administered immediately after 
induction of anesthesia. All patients received ondansetron 
20-30 minutes before the end of procedure.
Anesthetic technique
Anesthetic technique was standardized: we calculated the 
doses of anesthetic drugs for induction and maintenance 
of anesthesia based on the ideal weight (IW) and corrected 
weight (CW) of patients, in which IW = height in cm (-100 
for men and -105 for women) and CW = IW + [0.4 x (current 
weight - ideal weight)]. Thus, anesthesia was induced with IV 
propofol (2 mg.kg-1 CW), fentanyl (3 μg.kg-1 CW), and cisatra-
curium (0.1 mg.kg-1 IW) for tracheal intubation. Remifentanil 
(0.1-0.3 μg.kg-1.min-1 IW), isoﬂ urane (1%) in a mixture of 1:1 
oxygen and air, and additional dose of cisatracurium were 
given for maintenance if required. Neuromuscular block was 
reversed with IV neostigmine up to 0.04 mg.kg-1 and atropine 
up to 0.015 mg.kg-1.
Surgical technique
LSG was standardized. We insterted ﬁ ve or six trocars after 
establishing the pneumoperitoneum. Initially, partial release 
of the stomach’s greater curvature was done using the ultra-
sonic device Ligasure®, preserving the antral region. Then, 
we positioned an orogastric tube (Fouchet 32 French) into 
the lesser curvature to delimit gastric resection, which we 
performed with linear staplers 2 to 5 cm from the pylorus, 
advancing it to the angle of Hiss. After gastric tube insertion, 
we did a staple line reinforcement using non-absorbable mo-
noﬁ lament sutures with continuous invaginating seromuscular 
stitches. At the end of surgery, Fouchet tube was aspirated 
and removed after a leak test using methylene blue. 
Postoperative diet
We introduced fractionated oral liquid diet, initially with 
water and later with broth without residue, on the ﬁ rst pos-
toperative (PO) day, according to patient’s acceptance.
Verbal numeric scale of nausea (VNSN) and verbal 
numeric scale of pain (VNSP)
We evaluated nausea intensity by VNSN, ranging from 0 (no 
nausea) to 10 (worst possible nausea) and pain intensity by 
VNSP, ranging from 0 (no pain) to 10 (worst possible pain).
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Analgesia 
We administered intravenous ketorolac (30 mg) and dipyrone 
(20-30 mg.kg-1 IW) immediately after induction of anesthe-
sia and maintained it every 8 and 4 hours, respectively. We 
used intravenous bolus doses of morphine (2-3 mg) in post-
anesthesia care unit (PACU), if VNSP > 3. If VNSP > 3, we 
administered subcutaneous morphine (5 mg) after discharge 
to ward. 
Data collection
We recorded nausea and pain intensity at the end of 0-2, 
2-12, 12-24, and 24-36 hours postoperatively, in addition to 
the cumulative number of vomiting episodes and morphine 
consumption at 36 hours postoperatively. We also recorded 
the demographic variables: ASA physical status, non-smoker 
status, history of PONV, history of kinetosis, preoperative 
fasting time, duration of anesthesia, amount of ﬂ uids admi-
nistered during operation, and length of PACU stay.
Statistical analysis
We determined that the sample size of 28 patients per group 
was adequate to meet the decrease in mean nausea intensity 
from ﬁ ve to three in VNSN and standard deviation of three 
(pilot study showed a mean nausea intensity of three with 
the use of a prophylactic antiemetic drug), assuming a 20% 
β-error and 5%  α-error. 
We assessed continuous data with normal distribution 
using the analysis of variance test (ANOVA) followed by 
Tukey’s test for post-hoc analysis when necessary.
We assessed continuous or discrete data without nor-
mal distribution and ordinal data using Kruskal-Wallis test, 
followed by Mann-Whitney test for post-hoc analysis, if 
necessary. 
We used a Chi-square test for categorical data. We used 
repeated measures ANOVA test for comparative analysis 
of the evolution of variables: VNSN, VNSP, and morphine 
consumption over time between groups. In this analysis, 
we considered two factors of interest (time and group), in 
addition to the possible interaction between them.
To reject the null hypothesis, we established a level of sig-
niﬁ cance at 5% (p value < 0.05). We performed analyses using 
the Statistical Package for Social Sciences for Windows 17.0.
Results
Of the 96 randomized patients, six were excluded (one un-
derwent laparotomy, one had surgery postponed, two had 
surgical complications, one had angioneurotic edema, and 
one received rescue antiemetic outside the protocol). Thus, 
90 patients were included (30 per group). Demographic va-
riables, physical status, non-smoker status, history of PONV, 
history of kinetosis, preoperative fasting time, duration of 
anesthesia, amount of ﬂ uid administered during operation, 
and time of PACU stay had homogeneous distribution between 
the groups (Table l).
Nausea intensity
Nausea intensity was lower in Group HDO than in Group O 
(p = 0.001). Nausea intensity remained constant over time 
in all three groups (time variable, p = 0.17). There was no 
interaction between group and time (time variable x group, 
p = 0.96) (Fig. 1). 
Number of vomiting episodes
Kruskal-Wallis test showed a trend towards a statistical diffe-
rence between groups (p = 0.052). The number of vomiting 
episodes tended to be lower in Group HDO, followed by DO 
and O groups (Table 2). 
Pain intensity
Pain intensity was lower in Group HDO than in Group O (p 
= 0.046). There was also a decrease in pain intensity over 
time (p = 0.000). There was no interaction between group 
and time (time variable x group, p = 0.52) (Fig. 2).
Table 1 Demographic and Other Clinical Variables.
Group O
n = 30
Group DO
n = 30
Group HDO
n = 30
Weight (kg)a 118.7 ± 23.1 116.5 ± 25.1 111.9 ± 15.4
Height (metros)a 1.64 ± 0.1 1.65 ± 0.0 1.64 ± 0.0
BMI (Kg.cm-2)a 43.3 ± 7.4 41.9 ± 5.6 41.3 ± 3.8
Agea 34 ± 8 38 ± 11 37 ± 10 
Female (n, %) 21 (70) 19 (63.3) 21 (70)
ASA I/II/III 1/26/3 0/27/3 0/30/0
Non-smoker (n, %) 26 (86) 24 (80) 27 (90)
History of PONV (n, %) 8 (26.6) 10 (33.3) 7 (23.3)
History of kinetosis (n, %) 3 (10) 3 (10) 2 (6.6)
Fasting time (h)a 10.7 ± 1.9 11.4 ± 2.1 11.1 ± 1.4
Duration of anesthesia (min)a 154 ± 42 142 ± 24 146 ± 30
IV Fluid IV (L)b 2.74 (2-3.5) 2.71 (2-3.5) 2.65 (2-3.5)
PACU stay (min)b 175 (90-270) 177 (120-270) 140 (80-415)
DO, dexamethasone and ondansetron; HDO, haloperidol, dexamethasone, and ondansetron; PONV,postoperative nausea and 
vomiting; O, ondansetron.
aMean ± standard deviation.
bMedian and variations (minimum-maximum).
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Morphine consumption
Morphine consumption was lower in Group HDO than in 
Group O (p = 0.037). There was also a decrease in morphine 
consumption over time (p = 0.000). There was no interaction 
between group and time (time variable x group, p = 0.74) 
(Fig. 3).
Discussion
We chose haloperidol, dexamethasone, and ondansetron 
because they have different mechanisms of antiemetic 
activity, are inexpensive and have proven efﬁ cacy when 
used alone or in combination.11-14 We used haloperidol, in 
particular, because it is an interesting option to droperidol, 
as it provides less sedation.15
The selection of doses was based on previous studies re-
porting they were safe and effective.2,16 The study design did 
not include a control group without prophylactic medication. 
In fact, there is a higher incidence of PONV after laparoscopic 
surgeries and the use of balanced anesthesia.16 which in itself 
may justify the use of at least one prophylactic antiemetic 
drug; thus, we believe that it was not ethical to include a 
placebo group in this study.
In this study, patients received the same type of anes-
thesia and underwent the same type of surgery. Moreover, 
the variables age, gender, weight, height, physical status, 
BMI, non-smoker status, history of PONV and kinetosis, pre-
operative fasting time, duration of anesthesia, amount of 
ﬂ uid infused during surgery, and time of PACU stay (possible 
confounding biases) had homogeneous distribution between 
groups. This is important because the differences between 
groups could be attributed to the different antiemetic com-
binations administered.
The study showed that the combination of antiemetics 
reduced the intensity of nausea, proportionally to the 
number of drugs used. However, nausea intensity remained 
constant over time in all three groups. This may be explai-
ned by the additive effect of the antiemetic combination, 
Figure 1 Nausea intensity variation in verbal numerical scale 
of nausea (VNSN), according to group and time (hour).
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Figura 2 Variación de la intensidad del dolor por la escala 
numérica verbal de dolor (ENVD), segundo grupo y tiempo, 
en horas.
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Figura 3 Variación del consumo de morﬁ na, segundo grupo 
y tiempo, en horas. 
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Table 2 Number of Vomiting Episodes 36 Hours after Surgery, According to Group.
Group O
n = 30
Group DO
n = 30
Group HDO
n=30
p
Number of episodes 1.10 ± 1.2 0.83 ± 2 0.63 ± 1.2 0.052
DO, dexamethasone and ondansetron; HDO, haloperidol, dexamethasone, and ondansetron; O, ondansetron.
Data are expressed as mean and standard deviation.
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as suggested by Apfel.17 and the fact that haloperidol and 
dexamethasone elimination half-lives are greater than that 
of ondansetron. 
The number of vomiting episodes was not different be-
tween groups (p = 0.052), possibly because of the greater 
anti-vomiting than anti-nausea effect in antiemetics studied 
or the need for a larger sample size in order to ﬁ nd a statis-
tically signiﬁ cant difference.
Pain is a frequent cause of discomfort during the posto-
perative period. Pain intensity was lower in groups receiving 
dexamethasone, but statistically different in Group HDO 
compared to Group O. Pain relief effect may be attributed 
to the use of dexamethasone (decrease in proinﬂ ammatory 
cytokines release, such as tumor necrosis factor, interleukin-1 
and interleukin-6), similar to results of other studies.18-20
Morphine (IV and SC bolus) used as rescue analgesic was 
adequate, safe, and a good option compared to the use 
of IV morphine via patient-controlled analgesia. We found 
increased morphine consumption in the ﬁ rst 2 hours in all 
groups, with signiﬁ cant decline in subsequent periods. The 
use of dipyrone 21 and ketorolac 22 at ﬁ xed times may have 
contributed decisively to this result. There was less mor-
phine consumption in Group HDO than in Group O, which 
may be attributed to the anti-inﬂ ammatory and analgesic 
opioid-sparing action of dexamethasone, as seen in other 
studies.23-26
The combination of haloperidol, dexamethasone, and on-
dansetron decreased nausea and pain intensity and morphine 
consumption in obese patients undergoing LSG.
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